82,239,476 research outputs found
Inflammatory bowel diseases: clinical update of practical guidelines
No full textIdiopathic inflammatory bowel disease (IBD) includes a collection of disorders of the gastrointestinal tract of unknown aetiology, characterized by intestinal inflammation and a chronic relapsing course associated with local and systemic complications. Traditionally, IBD comprises two prototype entities, ulcerative colitis (UC) and Crohn's disease (CD) and an intermediate variant of these diseases, indeterminate colitis which shows overlapping features of the two major forms. Over the last few years, considerable progress has been made in our knowledge of the pathogenesis of IBD, which is complex and derives from genetic, environmental and immunological interactions. The aetiology remains unclear, but it is well established that the lesions and symptoms are associated with over-production of pro-inflammatory cytokines. In this paper we briefly review the pathophysiology and the new therapeutic approaches to IBD, since from these, new achievement depends the appropriate diagnostic exams to be performed and diagnostic flow charts. © 2005 Lippincott Williams & Wilkins, Inc
L’arbitro bancario finanziario, in Il diritto bancario oggi: aspetti sostanziali e processuali, a cura di F. Aratari – G. Romano, Wolters Kluwer
No full textSuitability of a conscription service nearby the observation department of the Military Hospital for legal medicine in Rome in 1994
No full textL'idoneita al servizio di leva presso il reparto di osservazione dell'O.M. di medicina legale di Roma nel 1994
No full textApplication to decayed tissues of a modified histological colouring for connective tissue
No full textTrichromatic colouring are often used to highlight connective tissue more effectively in cases of tissue at an advanced stage of decay. The authors present the results obtained by modifying Gomori's trichromic technique to cardiac tissue at various stages of decay
Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis
No full textBackground: Mucosa-infiltrated granulocyte neutrophils are an early characteristic of inflammation and the main histological feature of active ulcerative colitis. Mucosal healing has recently been indicated as an important tool in the evaluation of response to treatment. While several studies have stressed the efficacy of granulocyte-monocyte-apheresis in inducing clinical remission in active ulcerative colitis, few data are available on mucosal features. Aim: Aim of this study was to assess the effects of granulocyte-monocyte-apheresis on clinical and mucosal features in patients with ulcerative colitis, dependent upon or refractory to steroids. Material and methods: From April 2004 to April 2005, 12 patients (5 females, 7 males, mean age 49 years, range 33-71 years), with mild-moderate ulcerative colitis (six left colitis, six pancolitis) dependent/refractory upon steroids were enrolled. Each patient was treated for a 5-week period with five cycles of granulocyte-monocyte-apheresis. Patients were evaluated at baseline and 1 week after the last apheresis by means of Global Physician Assessment, quality of life features, laboratory tests (erythrocyte sedimentation rate, CRP, full blood count, faecal calprotectine), endoscopy and histology. Results: At week 6 of follow-up, complete mucosal healing was observed in 3 out of 12 patients, partial mucosal healing in 8 patients and no change in 1 patient. Clinical response was complete in 8 out of 12 patients. Conclusions: These data suggest that granulocyte-monocyte-apheresis induces an improvement both in clinical and mucosal lesions in steroid-dependent/refractory ulcerative colitis. Of note, the reduction in granulocyte infiltration and the improvement in mucosal lesions are accompanied by a reduction in faecal calprotectine. © 2005 Editrice Gastroenterologica Italiana S.r.l
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
APPLICAZIONE SU TESSUTI PUTREFATTI DI UNA COLORAZIONE ISTOLOGICA PER IL CONNETTIVO MODIFICATA
No full textTrichromatic colouring are often used to highlight connective tissue more effectively in cases of tissue at an advanced stage of decay. The authors present the results obtained by modifying Gomori's trichromic technique to cardiac tissue at various stages of decay
The advantages of patient's active involvement in the management of chronic Inflammatory Bowel Diseases
No full textThe patient's active involvement is an emerging hot-topic, which can be applied in to the management of chronic inflammatory bowel diseases (IBD). Since in this field most of the therapeutic strategies are not based on sturdy scientific evidences, the patient's role has become central and it is believed essential for any patients to have an active cognitive, behavioural and emotive profile. Moreover different patient's aspects should be considered, such as the patient's activation, the patient's engagement and the patient's disease knowledge. The initial evidences available on this topic within IBD context have showed how a higher patient's active profile and a deeper disease knowledge have had a positive effect on compliance, perceived health-care satisfaction, self-management and health costs. Therefore, considering the favourable outcomes so far highlighted, we hope that the evaluation of patient's involvement may become a standard procedure, allowing patients who need it to undergo active programmes which have proved to be effective in improving patient's degree of activation
Use of a Tc-99m labeled anti-TNF alpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies
No full textAim. Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by a cellular-mediated immune response driven by cytokines secreted mainly by T helper 1 cells (Th1). in active phases of the disease, an increased production and release of tumor necrosis factor alpha (TNF alpha) by macrophages and monocytes; of the lamina propria has been described. The aim of this study was to detect the presence of TNFa within the gut mucosa in patients with active CD by using Tc-99m-labelled chimeric human/mouse monoclonal antibody anti-TNF alpha (Infliximab, Remicade (R)).Methods. Infliximab has been labeled with Tc-99m after reduction of disulfide bound by 2-ME method. In vitro binding assay and biodistribution in animal of [Tc-99m]Infliximab has been performed to evaluate the retention of its biological activity. Ten patients with active CD refractory to conventional medical therapies were studied. images of the abdomen were acquired at 6 to 20 h after i.v. injection of about 10 mCi of [Tc-99m]Infliximab and a week later, all patients were also studied with [Tc-99m]HMPAO-labeled autologous white blood cells (WBC).Results. A product with high labeling efficiency (>95%) and stability has been obtained. In vitro tests with stimulated T-cells expressing TNFa indicated that [Tc-99m] Infliximab retains its binding activity to cell bound TNFa as compared to unlabelled Infliximab. The degree of [Tc-99m]Infliximab uptake by the inflamed bowel evaluated at 20 h postinjection was much less than that seen with labeled WBC and with a different distribution. Three of these patients received anti-TNF alpha (Infliximab) for therapeutic purposes with good clinical results despite the scintigraphy with Tc-99m-Infliximab was negative in 2 of them.Conclusion Scintigraphy with [Tc-99m]Infliximab shows the presence of little TNF alpha in the affected bowel of patients with active CD. Therefore, the clinical benefit that patients have from Infliximab therapy is unlikely die consequence of a local a reduction of TNF alpha and the mechanism of action of Infliximab, in therapeutic doses, deserves further investigations
- …
